Illumina price to free cash flow ILMN
Market value divided by free cash flow over the last twelve months, since 2011.
- Today, Nov 3, 2026
- 38.4×
- 10-year median
- 56.6×
- Against its 10-year history
- 18th
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 13.7× to 337×
- Peer median
- 29.0×
Illumina's price to free cash flow is 38.4× as of Nov 3, 2026.
That is below its ten-year median of 56.6×, lower than on 82% of days in the last ten years.
Over that time it ranged from 13.7× in Sep 2025 to 337× in Mar 2023.
The median for 10 diagnostics and research stocks of a similar size is 29.0×.
Price to free cash flow over time
The dashed line is the 10-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 36.7× | 18.3× | 45.1× |
| 2025 | 20.6× | 13.7× | 39.6× |
| 2024 | 39.2× | 39.2× | 132× |
| 2023 | 127× | 86.1× | 337× |
| 2022 | 119× | 107× | 189× |
| 2021 | 123× | 57.2× | 132× |
| 2020 | 56.3× | 39.6× | 69.4× |
| 2019 | 68.7× | 48.7× | 68.7× |
| 2018 | 51.4× | 48.1× | 69.5× |
| 2017 | 56.8× | 46.4× | 61.5× |
| 2016 | 42.2× | 37.3× | 60.2× |
| 2015 | 65.4× | 52.6× | 82.4× |
| 2014 | 66.8× | 49.5× | 88.1× |
| 2013 | 50.3× | 24.1× | 50.3× |
| 2012 | 27.1× | 14.0× | 27.9× |
| 2011 | 13.4× | 11.8× | 36.3× |
Against its peers
Companies in Medical - Diagnostics & Research nearest Illumina's size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| ILMNIllumina | 38.4× |
| MTDMettler-Toledo International | 39.6× |
| LHLabcorp | 25.0× |
| DGXQuest Diagnostics | 20.0× |
| IQVIQVIA | 19.4× |
| WATWaters | 117× |
| AAgilent Technologies | 39.1× |
| IDXXIDEXX Laboratories | 41.5× |
| MEDPMedpace | 25.6× |
| RVTYRevvity | 30.3× |
| BIOBio-Rad Laboratories | 27.7× |
| Peer median | 29.0× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Illumina
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.